1.	Phase III Study of Adjuvant Autolymphocyte Therapy for T1-3 N1-3 M0 or T4 N0-3 M0 Renal Cell Carcinoma (Summary Last Modified 12/93) Phase: Phase III Type: Treatment Status: Closed Age: over 18 Sponsor: Protocol IDs: CUCCC-90-C01, NCI-V91-0009
2.	Phase I/II Study of Activated Cytotoxic T Cells and Low-Dose Continuous-Infusion Interleukin-2 in Advanced Cancers (Summary Last Modified 09/98) Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: STLMC-BRM-9502, NCI-V95-0764
3.	Phase I/II Study of an Anti-T3 MoAb (OKT3) in Patients with Lymphoproliferative Disorders Bearing the T3 Antigen (Summary Last Modified 03/90) Phase: Phase II, Phase I Type: Treatment Status: Completed Age: over 18 Sponsor: NCI Protocol IDs: BRMP-8707B, NCI-87-C-99B, NCI-T87-0175N, T87-0175
4.	Phase I/II Study of MOAB OKT3 with Low-Dose CTX in Patients with Advanced Malignancies (Summary Last Modified 09/2001). Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: SVMC-ONC-121, NCI-V90-0206, NCT00002482
5.	Haploidentical Transplantation With CD3/CD19 Depleted Grafts in Patients With Hematologic Malignancies Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 to 60 Sponsor: Other Protocol IDs: E203/2004, IRB Project Nr. 21/2004, HSZ-001, NCT00202917
6.	Phase II Study of Autologous Tumor Cell Vaccine Therapy Followed by Adoptive Immunotherapy with Peripheral Blood Mononuclear Cells/IL-2 for Stage IV Melanoma (Summary Last Modified 07/94) Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: KUMC-5699-93, NCI-V94-0426
7.	Phase II Study of Muromonab-CD3 (Orthoclone OKT3) plus Steroids and Cyclosporine in Acute Graft Versus Host Disease Prophylaxis Therapy Following Allogeneic Bone Marrow Transplantation (Summary Last Modified 12/1999) Phase: Phase II Type: Supportive care, Treatment Status: Closed Age: 5 to 65 Sponsor: NCI Protocol IDs: RPCI-DS-96-67, NCI-G97-1247
8.	Phase II Study of Adoptive Cellular Therapy of Cancer Combining Direct HLA-B7/beta 2-Microglobulin Gene Transfer with Autologous Tumor Inoculation for the Generation of Tumor-Primed Anti-CD3 Activated Lymphocytes in Patients with Metastatic Renal Cell Carcinoma or Melanoma (Summary Last Modified 09/98) Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: PPMC-IRB-94-53, OCC-ONC-9513-L, NCI-V98-1378
9.	Biological Therapy Following Surgery and Chemotherapy in Treating Patients With Stage III or Stage IV Breast Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000067236, WSU-C-1403-BR, NCI-G99-1561, NCT00004018
10.	Biological Therapy Following Surgery and Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Lung Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000067238, WSU-C-1403-LU, NCI-G99-1562, NCT00004019
11.	Biological Therapy Following Surgery and Chemotherapy in Treating Patients With Stage III or Stage IV Colon Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000067239, WSU-C-1403-CO, NCI-G99-1563, NCT00004020
12.	Biological Therapy Following Surgery and Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000067240, WSU-C-1403-OV, NCI-G99-1564, NCT00004021
13.	Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Melanoma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000067241, P30CA022453, WSU-C-1403-ME, NCI-G99-1565, NCT00004022
14.	Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Kidney Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000067242, WSU-C-1403-RN, NCI-G99-1566, NCT00004023
15.	Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or Oligodendroglioma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000067243, P30CA022453, WSU-C-1403-BT, NCI-G99-1567, NCT00004024
16.	Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies Phase: Phase II Type: Treatment Status: Completed Age: 2 to 21 Sponsor: Other Protocol IDs: HAPREF, NCT00143559
17.	Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 45 and under Sponsor: NCI, Other Protocol IDs: 1965.00, R01AI053193, P30CA015704, FHCRC-1965.00, CDR0000533834, 6428, NCT00450983
18.	Lymphocyte Therapy in Treating Patients With Kidney Cancer Phase: Phase II Type: Treatment Status: Closed Age: Over 16 Sponsor: Other Protocol IDs: CDR0000063744, STLMC-BRM-9401, NCI-V94-0514, NCT00002589
19.	Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma Phase: Phase II Type: Treatment Status: Completed Age: 16 and over Sponsor: NCI Protocol IDs: 040152, 04-C-0152, NCT00080353
20.	Phase I Pilot Study of MOAB OKT3 in Patients with T-Cell (CD3+) Malignancies (Summary Last Modified 05/97) Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: CRB-9404, NCI-T93-0197N, T93-0197
21.	Phase I Study of In Vitro Anti-CD3-Stimulated CD4+ T-Cell Subsets Given in Combination with Systemic IL-2 and CTX in Patients with Advanced Malignancies (Summary Last Modified 06/97) Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-96-C-0134, CRB-9302, NCI-T93-0171N, T93-0171
22.	Cytotoxic T Cells and Interleukin-2 in Treating Adult Patients With Recurrent Brain Tumors Phase: Phase I Type: Treatment Status: Completed Age: Over 18 Sponsor: NCI, Other Protocol IDs: 93-0426, UCHSC-COMIRB-93426, NCI-T94-0065O, T94-0065, NCT00002572
23.	Phase IB Study of Anti-CD3 MOAB OKT3 plus IL-2 for Advanced Melanoma and Renal Cell Carcinoma (Summary Last Modified 08/97) Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-96-C-0131, CRB-9207, NCI-T94-0083N, T94-0083
24.	Phase I Study of Cytotoxic T-Cell Infusion with PBSC Transplantation for Acute Leukemia, Hodgkin's Disease, non-Hodgkin's Lymphoma, and Multiple Myeloma (Summary Last Modified 04/1999) Phase: Phase I Type: Treatment Status: Completed Age: 13 and over Sponsor: Other Protocol IDs: STLMC-BRM-9501, NCI-V95-0735
25.	Phase I Study of Anti-CD3 Monoclonal Antibodies in Patients with Advanced Cancer (Summary Last Modified 04/90) Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: BRMP-8805B, NCI-89-C-44B, NCI-T88-0269N, T88-0269